Neurocrine CCO gets 6,275 shares on PRSU vest

NBIX’s Chief Commercial Officer reported PRSU-based share vesting, with part of the shares withheld to cover taxes and no open-market sales.

Rhea-AI Filing Summary

Neurocrine Biosciences Inc. (NBIX) reported that Chief Commercial Officer Eric Benevich received a grant/award acquisition of 6,275 shares of common stock on September 11, 2026 upon certification of a performance metric under previously granted PRSUs. On the same date, the company withheld 3,386 shares at $156.22 per share to satisfy tax withholding requirements on the vesting; the filing states that no shares were sold and no Rule 10b5-1 trading plan is reported.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider BENEVICH ERIC

Role Chief Commercial Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	6,275	$0.00	$0.00
Tax Withholding	Common Stock F2	3,386	$156.22	$529K

Holdings After Transaction: Common Stock — 67,297 shares (Direct)

Footnotes (2)

1. F1. The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026.
2. F2. Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold.

Key Figures

Shares acquired from PRSU vesting: 6,275 shares Shares withheld for taxes: 3,386 shares Tax withholding reference price: $156.22 per share +1 more

4 metrics

Shares acquired from PRSU vesting 6,275 shares Common stock granted/awarded to Chief Commercial Officer on September 11, 2026

Shares withheld for taxes 3,386 shares Withheld by Neurocrine Biosciences to satisfy tax withholding on PRSU vesting

Tax withholding reference price $156.22 per share Price used for the 3,386 shares withheld for tax withholding on September 11, 2026

Performance certification date September 11, 2026 Date on which achievement of one PRSU performance metric was certified

Key Terms

performance restricted stock units (PRSUs), vest upon the achievement of certain performance metrics, tax withholding requirements

3 terms

performance restricted stock units (PRSUs) financial

"The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement..."

vest upon the achievement of certain performance metrics financial

"PRSUs that vest upon the achievement of certain performance metrics, the achievement of one of which was certified..."

tax withholding requirements financial

"Shares withheld by Neurocrine Biosciences, Inc. to satisfy tax withholding requirements on vesting of PRSUs."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did NBIX report for Chief Commercial Officer Eric Benevich?

NBIX reported that Chief Commercial Officer Eric Benevich acquired 6,275 shares of common stock on September 11, 2026 from the vesting of previously granted performance restricted stock units (PRSUs), after a specified performance metric was certified as achieved.

How many NBIX shares were withheld for taxes in this Form 4?

The company withheld 3,386 shares of Neurocrine Biosciences common stock on September 11, 2026 to satisfy tax withholding requirements related to the vesting of PRSUs, at a reported price of $156.22 per share.

Were any NBIX shares sold on the open market in this Form 4 transaction?

No. A footnote states that the 3,386 shares were withheld by Neurocrine Biosciences to satisfy tax withholding requirements on PRSU vesting, and explicitly clarifies that no shares were sold.

What triggered the NBIX PRSU vesting for Eric Benevich on September 11, 2026?

The vesting was triggered when one performance metric tied to previously granted performance restricted stock units (PRSUs) was certified as achieved on September 11, 2026, leading to the issuance of 6,275 shares of common stock.

Was the NBIX Form 4 transaction made under a Rule 10b5-1 trading plan?

No. The filing’s Rule 10b5-1 checkbox is not marked as affirmative, and the footnotes describe vesting of PRSUs and tax withholding, with no indication that these transactions were executed under a Rule 10b5-1 trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/15/2026 - 05:03 PM Accepted by SEC EDGAR 09/15/2026 - 05:02 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BENEVICH ERIC

(Last) (First) (Middle)

6027 EDGEWOOD BEND CT.

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NEUROCRINE BIOSCIENCES INC [ NBIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/11/2026		A(1)		6,275	A	$0	70,683	D
Common Stock	09/11/2026		F(2)		3,386	D	$156.22	67,297	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026.

2. Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold.

Remarks:

	/s/ Darin Lippoldt, Attorney-in-Fact	09/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)